AKT signaling is associated with epigenetic reprogramming via the upregulation of TET and its cofactor, alpha-ketoglutarate during iPSC generation.
AKT signal
DNA demethylation
Reprogramming
TET
iPS cells
αKG
Journal
Stem cell research & therapy
ISSN: 1757-6512
Titre abrégé: Stem Cell Res Ther
Pays: England
ID NLM: 101527581
Informations de publication
Date de publication:
25 09 2021
25 09 2021
Historique:
received:
11
05
2021
accepted:
31
08
2021
entrez:
26
9
2021
pubmed:
27
9
2021
medline:
30
10
2021
Statut:
epublish
Résumé
Phosphoinositide-3 kinase (PI3K)/AKT signaling participates in cellular proliferation, survival and tumorigenesis. The activation of AKT signaling promotes the cellular reprogramming including generation of induced pluripotent stem cells (iPSCs) and dedifferentiation of primordial germ cells (PGCs). Previous studies suggested that AKT promotes reprogramming by activating proliferation and glycolysis. Here we report a line of evidence that supports the notion that AKT signaling is involved in TET-mediated DNA demethylation during iPSC induction. AKT signaling was activated in mouse embryonic fibroblasts (MEFs) that were transduced with OCT4, SOX2 and KLF4. Multiomics analyses were conducted in this system to examine the effects of AKT activation on cells undergoing reprogramming. We revealed that cells undergoing reprogramming with artificially activated AKT exhibit enhanced anabolic glucose metabolism and accordingly increased level of cytosolic α-ketoglutarate (αKG), which is an essential cofactor for the enzymatic activity of the 5-methylcytosine (5mC) dioxygenase TET. Additionally, the level of TET is upregulated. Consistent with the upregulation of αKG production and TET, we observed a genome-wide increase in 5-hydroxymethylcytosine (5hmC), which is an intermediate in DNA demethylation. Moreover, the DNA methylation level of ES-cell super-enhancers of pluripotency-related genes is significantly decreased, leading to the upregulation of associated genes. Finally, the transduction of TET and the administration of cell-permeable αKG to somatic cells synergistically enhance cell reprogramming by Yamanaka factors. These results suggest the possibility that the activation of AKT during somatic cell reprogramming promotes epigenetic reprogramming through the hyperactivation of TET at the transcriptional and catalytic levels.
Sections du résumé
BACKGROUND
Phosphoinositide-3 kinase (PI3K)/AKT signaling participates in cellular proliferation, survival and tumorigenesis. The activation of AKT signaling promotes the cellular reprogramming including generation of induced pluripotent stem cells (iPSCs) and dedifferentiation of primordial germ cells (PGCs). Previous studies suggested that AKT promotes reprogramming by activating proliferation and glycolysis. Here we report a line of evidence that supports the notion that AKT signaling is involved in TET-mediated DNA demethylation during iPSC induction.
METHODS
AKT signaling was activated in mouse embryonic fibroblasts (MEFs) that were transduced with OCT4, SOX2 and KLF4. Multiomics analyses were conducted in this system to examine the effects of AKT activation on cells undergoing reprogramming.
RESULTS
We revealed that cells undergoing reprogramming with artificially activated AKT exhibit enhanced anabolic glucose metabolism and accordingly increased level of cytosolic α-ketoglutarate (αKG), which is an essential cofactor for the enzymatic activity of the 5-methylcytosine (5mC) dioxygenase TET. Additionally, the level of TET is upregulated. Consistent with the upregulation of αKG production and TET, we observed a genome-wide increase in 5-hydroxymethylcytosine (5hmC), which is an intermediate in DNA demethylation. Moreover, the DNA methylation level of ES-cell super-enhancers of pluripotency-related genes is significantly decreased, leading to the upregulation of associated genes. Finally, the transduction of TET and the administration of cell-permeable αKG to somatic cells synergistically enhance cell reprogramming by Yamanaka factors.
CONCLUSION
These results suggest the possibility that the activation of AKT during somatic cell reprogramming promotes epigenetic reprogramming through the hyperactivation of TET at the transcriptional and catalytic levels.
Identifiants
pubmed: 34563253
doi: 10.1186/s13287-021-02578-1
pii: 10.1186/s13287-021-02578-1
pmc: PMC8467031
doi:
Substances chimiques
DNA-Binding Proteins
0
Ketoglutaric Acids
0
Klf4 protein, mouse
0
Kruppel-Like Factor 4
0
Proto-Oncogene Proteins c-akt
EC 2.7.11.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
510Informations de copyright
© 2021. The Author(s).
Références
Mol Cell. 2014 Jul 17;55(2):253-63
pubmed: 24882210
Cell Metab. 2016 Apr 12;23(4):663-74
pubmed: 27050306
Cell. 2012 Dec 21;151(7):1617-32
pubmed: 23260147
EMBO Rep. 2018 Dec;19(12):
pubmed: 30413482
Cell Metab. 2017 May 2;25(5):1103-1117.e6
pubmed: 28467928
Cell Stem Cell. 2015 May 7;16(5):547-55
pubmed: 25865501
Stem Cells. 2014 Feb;32(2):349-63
pubmed: 23765875
Mol Cell. 2012 Nov 30;48(4):627-40
pubmed: 23041284
Cold Spring Harb Protoc. 2014 Oct 01;2014(10):pdb.prot080002
pubmed: 25275104
Cell Rep. 2016 Sep 27;17(1):19-28
pubmed: 27681417
Nucleic Acids Res. 2008 Jul 1;36(Web Server issue):W170-5
pubmed: 18487274
Cell Cycle. 2015;14(23):3748-54
pubmed: 26654770
Cell. 2017 Mar 9;168(6):1000-1014.e15
pubmed: 28283057
Cell Stem Cell. 2010 Jul 2;7(1):51-63
pubmed: 20621050
Sci Rep. 2016 Dec 08;6:38299
pubmed: 27929071
Cell Metab. 2011 Aug 3;14(2):264-71
pubmed: 21803296
World J Stem Cells. 2016 Aug 26;8(8):251-9
pubmed: 27621759
Development. 2018 Oct 1;145(19):
pubmed: 30275240
Cell. 2006 Aug 25;126(4):663-76
pubmed: 16904174
Dev Growth Differ. 1999 Dec;41(6):675-84
pubmed: 10646797
Cell Stem Cell. 2013 Apr 4;12(4):453-69
pubmed: 23499384
Nature. 2014 Feb 13;506(7487):235-9
pubmed: 24336202
Cell Stem Cell. 2018 Nov 1;23(5):727-741.e9
pubmed: 30220521
PLoS One. 2016 May 03;11(5):e0154770
pubmed: 27138223
Mol Cell Biol. 2015 Mar;35(6):1026-42
pubmed: 25582196
Cell Rep. 2017 Jan 31;18(5):1079-1089
pubmed: 28147265
Development. 2008 Mar;135(5):869-79
pubmed: 18216173
Nature. 2012 Aug 30;488(7413):652-5
pubmed: 22902501
Nature. 2009 Dec 3;462(7273):595-601
pubmed: 19898493
Development. 2003 Apr;130(8):1691-700
pubmed: 12620992
Nucleic Acids Res. 2017 Feb 28;45(4):e24
pubmed: 28204635
Nat Genet. 2008 Feb;40(2):243-8
pubmed: 18176565
Bioinformatics. 2010 Jan 1;26(1):139-40
pubmed: 19910308
EMBO J. 2019 Jan 3;38(1):
pubmed: 30257965
Nature. 2016 Jan 14;529(7585):216-20
pubmed: 26735015
Sci Rep. 2019 Jul 9;9(1):9919
pubmed: 31289326
Cell. 2014 Feb 13;156(4):649-62
pubmed: 24486105
Nucleic Acids Res. 2019 May 21;47(9):4449-4461
pubmed: 30838422
Development. 1996 Mar;122(3):881-94
pubmed: 8631266
Cancer Cell. 2011 Jan 18;19(1):17-30
pubmed: 21251613
Cell Metab. 2016 Sep 13;24(3):485-493
pubmed: 27476976
Oncogene. 2006 May 4;25(19):2697-707
pubmed: 16407845
Cell. 2017 Apr 20;169(3):381-405
pubmed: 28431241
Nat Immunol. 2017 Dec;18(12):1342-1352
pubmed: 29058703
Oncogene. 2007 Jul 19;26(33):4882-8
pubmed: 17297448
Cell Stem Cell. 2018 Aug 02;23(2):289-305.e5
pubmed: 30017590
Nat Methods. 2017 Apr;14(4):417-419
pubmed: 28263959